Genesis IBRC India (GENESIS) | Stock Overview & Key Data
Genesis IBRC India Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹184.90 on November 11, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Genesis IBRC India
GENESIS
|
4.47B Small-cap | 0.00% | -0.51% | 54.94% | -14.33% | 37.72% | 507.27% | 993.55% | 1,467.02% | 623.84% | 5,745.00% | 5,745.00% |
|
Biocon
BIOCON
|
566.52B Large-cap | -4.44% | 15.59% | 7.44% | 4.46% | 7.49% | 27.63% | 78.42% | 11.37% | 265.74% | 609.92% | 1,204.47% |
|
OneSource Specialty
ONESOURCE
|
202.76B Large-cap | 1.27% | 4.12% | 39.64% | 12.39% | 2.29% | -5.07% | 6.70% | 6.70% | 6.70% | 6.70% | 6.70% |
|
Zota Health Care
ZOTA
|
39.41B Small-cap | -2.47% | -13.95% | -6.24% | -28.72% | -24.79% | 12.58% | 278.03% | 548.16% | 1,137.98% | 1,137.98% | 1,137.98% |
|
Dishman Carbogen
DCAL
|
26.50B Small-cap | -0.71% | 6.84% | 15.89% | -15.76% | -22.37% | -26.89% | 58.94% | -7.70% | 27.01% | 314.26% | 123.54% |
|
Panacea Biotec
PANACEABIO
|
21.84B Small-cap | 1.54% | 15.38% | 31.92% | 21.66% | 14.02% | -22.18% | 242.47% | 5.32% | 298.85% | 175.16% | 35.76% |
Ownership & Short Interest
Calculate Your Genesis IBRC India Investment Returns
Long-Term Investment Performance Analysis
Genesis IBRC India stock price in Dec 2020 was ₹7.46, A ₹1,000.00 lump sum investment in Genesis IBRC India made 5 years ago would be worth approximately ₹14,892.76 today, representing a exceptional return of 1,389.28%. This translates to an annualized return (CAGR) of 64.46%.
5 Years 5 Months Investment Scenario (Dec 2020 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is GENESIS's 52-week high and low?
- In the last 52 weeks, Genesis IBRC India reached a high of ₹181.30 (on November 10, 2025) and a low of ₹19.25 (on June 6, 2025).
- What is the market cap and P/E ratio for GENESIS?
- Curious about Genesis IBRC India's size and valuation? Its market capitalization stands at 4.47B. When it comes to valuation, the P/E ratio (trailing twelve months) is 57.89, and the forward P/E (looking ahead) is N/A.
- Does GENESIS pay dividends? If so, what's the yield?
- As for dividends, Genesis IBRC India isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Genesis IBRC India's main competitors or similar companies to consider before investing?
When looking at Genesis IBRC India, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Biocon
BIOCON566.52B Healthcare Biotechnology 27.63% 78.42% OneSource Specialty
ONESOURCE202.76B Healthcare Biotechnology -5.07% 6.70% Zota Health Care
ZOTA39.41B Healthcare Biotechnology 12.58% 278.03% Dishman Carbogen
DCAL26.50B Healthcare Biotechnology -26.89% 58.94% Panacea Biotec
PANACEABIO21.84B Healthcare Biotechnology -22.18% 242.47% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Genesis IBRC India Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Genesis IBRC India's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 0.08%, the Debt to Equity ratio from the most recent quarter is 0.00, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for GENESIS?
- Looking at Genesis IBRC India's growth, its revenue over the trailing twelve months (TTM) was INR3M. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of GENESIS stock is held by insiders and institutions?
- Wondering who owns Genesis IBRC India stock? Company insiders (like executives and directors) hold about 27.24% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.